Functional elements in initiation factors 1, 1A, and 2β discriminate against poor AUG context and non-AUG start codons.

Mol Cell Biol

Laboratory of Gene Regulation and Development, Eunice K. Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

Published: December 2011

Yeast eIF1 inhibits initiation at non-AUG triplets, but it was unknown whether it also discriminates against AUGs in suboptimal context. As in other eukaryotes, the yeast gene encoding eIF1 (SUI1) contains an AUG in poor context, which could underlie translational autoregulation. Previously, eIF1 mutations were identified that increase initiation at UUG codons (Sui(-) phenotype), and we obtained mutations with the opposite phenotype of suppressing UUG initiation (Ssu(-) phenotype). Remarkably, Sui(-) mutations in eukaryotic translation initiation factor 1 (eIF1), eIF1A, and eIF2β all increase SUI1 expression in a manner diminished by introducing the optimal context at the SUI1 AUG, whereas Ssu(-) mutations in eIF1 and eIF1A decrease SUI1 expression with the native, but not optimal, context present. Therefore, discrimination against weak context depends on specific residues in eIFs 1, 1A, and 2β that also impede selection of non-AUGs, suggesting that context nucleotides and AUG act coordinately to stabilize the preinitiation complex. Although eIF1 autoregulates by discriminating against poor context in yeast and mammals, this mechanism does not prevent eIF1 overproduction in yeast, accounting for the hyperaccuracy phenotype afforded by SUI1 overexpression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232919PMC
http://dx.doi.org/10.1128/MCB.05819-11DOI Listing

Publication Analysis

Top Keywords

context
8
sui1 aug
8
poor context
8
eif1 eif1a
8
sui1 expression
8
optimal context
8
eif1
7
initiation
5
sui1
5
functional elements
4

Similar Publications

Purpose: This study explores how corporate social responsibility (CSR) and artificial intelligence (AI) can be combined in the healthcare industry during the post-COVID-19 recovery phase. The aim is to showcase how this fusion can help tackle healthcare inequalities, enhance accessibility and support long-term sustainability.

Design/methodology/approach: Adopting a viewpoint approach, the study leverages existing literature and case studies to analyze the intersection of CSR and AI.

View Article and Find Full Text PDF

Background: Archetypes are representations of a group of people with shared behaviors, attitudes, and characteristics. The design and use of archetypes have potential application to increase partnership and support when embedding and scaling interventions but methodological approaches have not been developed.

Objective: To describe the methodology of designing archetypes for use in a pragmatic trial of advance care planning in the primary care context, SHARING Choices ((NCT04819191).

View Article and Find Full Text PDF

The development of a newly fabricated ion-selective electrode (ISE) solid-contacted type for the determination of prucalopride succinate represents a significant advancement in analytical chemistry, particularly in the context of green chemistry principles. The optimization process involved numerous trials to ensure the selection of a cation exchanger and ionophore that offer high sensitivity and selectivity for prucalopride succinate. Through these optimization trials, sodium tetrakis was identified as the most suitable cation exchanger, while calix [8] arene demonstrated the highest affinity towards prucalopride succinate as the ionophore.

View Article and Find Full Text PDF

Background: The initial theme of the PROGRESS framework for prognosis research is termed overall prognosis research. Its aim is to describe the most likely course of health conditions in the context of current care. These average group-level prognoses may be used to inform patients, health policies, trial designs, or further prognosis research.

View Article and Find Full Text PDF

mRNA vaccines in the context of cancer treatment: from concept to application.

J Transl Med

January 2025

Department of Biochemistry and Molecular Biology, Binzhou Medical University, 346 Guanhai Road, Yantai, 264003, P. R. China.

Immuno-oncology has witnessed remarkable advancements in the past decade, revolutionizing the landscape of cancer therapeutics in an encouraging manner. Among the diverse immunotherapy strategies, mRNA vaccines have ushered in a new era for the therapeutic management of malignant diseases, primarily due to their impressive impact on the COVID-19 pandemic. In this comprehensive review, we offer a systematic overview of mRNA vaccines, focusing on the optimization of structural design, the crucial role of delivery materials, and the administration route.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!